{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-V5C321IC/77e00a8d-77da-45e9-86a0-a4d8b4e4b530/PDF","dcterms:extent":"1808 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-V5C321IC/6a9416c3-f299-4568-8e02-13742a0f8ef0/TEXT","dcterms:extent":"26 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-V5C321IC","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2022","dc:creator":["Avsec, Damjan","Mlinarič-Raščan, Irena","Podgornik, Helena","Škerget, Matevž"],"dc:format":[{"@xml:lang":"sl","#text":"številka:5"},{"@xml:lang":"sl","#text":"letnik:73"},{"@xml:lang":"sl","#text":"str. 410-417"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:132626435","URN:URN:NBN:SI:doc-V5C321IC"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"akalabrutinib"},{"@xml:lang":"sl","#text":"BTK"},{"@xml:lang":"sl","#text":"ibrutinib"},{"@xml:lang":"sl","#text":"Imunoterapija"},{"@xml:lang":"sl","#text":"Kronična limfocitna levkemija"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Tarčno zdravljenje kronične limfocitne levkemije z zaviralci Brutonove tirozin kinaze| Targeting Bruton’s tyrosine kinase in chronic lymphocytic leukemia|"},"dc:description":[{"@xml:lang":"sl","#text":"Chronic lymphocytic leukemia (CLL) is characterised by the progressive accumulation of monoclonal B lymphocytes in the blood and lymphoid organs, and represents the most prevalent leukemia among adults in Slovenia. In the last decade, CLL treatment has undergone a radical change, as the standard of care chemoimmunotherapy has been replaced by small targeted molecules. The first among them are selective inhibitors of Bruton's tyrosine kinase (ibrutinib, acalabrutinib) and phosphatidylinositol 3- kinase (idelalisib, duvelisib), which target B-cell receptor signalling pathway of lymphocytes B. In this review, we present the development, significance and future of Bruton’s tyrosine kinase inhibitors in the targeted therapy of CLL"},{"@xml:lang":"sl","#text":"Kronična limfocitna levkemija (KLL) je bolezen kopičenja monoklonskih limfocitov B v krvi in limfatičnih organih in predstavlja najpogostejšo levkemijo pri odraslih v Sloveniji. V zadnjem desetletju je zdravljenje KLL doživelo korenito prenovo, saj so zlati standard kemoimunoterapijo nadomestile majhne tarčne molekule. Prvi v tej vrsti so zaviralci Brutonove tirozin kinaze (ibrutinib, akalabrutinib) in fosfatidilinozitol 3-kinaze (idelalizib, duvelizib), ki delujejo na receptorsko pot limfocitov B. V tem članku predstavljamo razvoj, pomen in prihodnost zaviralcev Brutonove tirozin kinaze pri tarčnem zdravljenju KLL"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-V5C321IC","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-V5C321IC"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-V5C321IC/77e00a8d-77da-45e9-86a0-a4d8b4e4b530/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-V5C321IC/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-V5C321IC"}}}}